Cefiderocol Activity in Resistant European Non-Fermenters

Carbapenem-resistant non-fermenting Gram-negative bacteria are difficult to treat because resistance often combines reduced permeability, active efflux, and β-lactamase production. The reference study by Santerre Henriksen and colleagues examined this problem in a large European isolate collection, focusing on cefiderocol activity against Pseudomonas aeruginosa and Acinetobacter spp. The work is particularly useful because it did not restrict analysis to broadly susceptible organisms: it deliberately included isolates resistant to meropenem and to newer β-lactam/β-lactamase inhibitor combinations.

The paper should be read as a regional, in vitro surveillance and resistance-mechanism study rather than as a clinical outcomes trial. Its main contribution is the direct comparison of cefiderocol with multiple contemporary comparators, followed by targeted molecular analysis of resistant subsets. The full study is available through the reference article.

Study Background and Research Question

P. aeruginosa and Acinetobacter spp. are major hospital pathogens, especially in respiratory and other infections involving critically ill patients. Carbapenem resistance narrows treatment choices, while resistance to ceftazidime-avibactam, ceftolozane-tazobactam, and other newer combinations can further complicate empirical and directed therapy. These organisms are therefore important targets for surveillance that measures activity across several agents rather than reporting resistance to a single drug.

The study asked two linked questions. First, how active is cefiderocol against European clinical isolates of P. aeruginosa and Acinetobacter spp. compared with meropenem and recent β-lactam/β-lactamase inhibitor combinations? Second, which genetic features are detectable among meropenem-resistant or cefiderocol-resistant isolates? This design allowed the investigators to evaluate both comparative susceptibility and possible explanations for the small cefiderocol-resistant subgroups.

Key Innovation from the Reference Study

The central innovation was the breadth and structure of the comparison. Isolates were collected from 49 sites in six European countries during 2020, and cefiderocol was tested alongside a broad panel that included licensed and non-licensed β-lactam/β-lactamase inhibitor combinations. According to the reference study, this was the first investigation to make this direct in vitro comparison against both P. aeruginosa and Acinetobacter spp. while emphasizing meropenem- and combination-resistant phenotypes.

A second important design choice was the use of a meropenem resistance definition based on an MIC greater than 8 mg/L. This threshold reflected resistance to high-dose meropenem, helping the analysis focus on isolates that would remain problematic even when an intensified meropenem regimen might otherwise be considered. The paper therefore addresses a clinically relevant resistance population rather than a nominally resistant group defined by a less stringent threshold.

The molecular component also adds value. Meropenem-resistant, cefiderocol-susceptible isolates underwent PCR analysis, whereas cefiderocol-resistant isolates underwent whole-genome sequencing. This tiered strategy concentrated deeper genomic work on the rarest and most informative phenotypes, producing a more efficient link between susceptibility results and candidate resistance mechanisms.

Methods and Experimental Design Insights

The investigators analyzed 1,451 non-fermenting Gram-negative isolates: 950 P. aeruginosa and 501 Acinetobacter spp. Respiratory specimens were common sources, accounting for 42.0% of the P. aeruginosa collection and 39.3% of the Acinetobacter collection, as reported in the published dataset. Each isolate was assessed using an in vitro antibacterial susceptibility assay against cefiderocol and the comparator agents. The analysis then separated overall populations from meropenem-resistant and β-lactam/β-lactamase inhibitor-resistant subsets.

For mechanism analysis, PCR was used to characterize β-lactamase genes in meropenem-resistant but cefiderocol-susceptible isolates. Whole-genome sequencing was applied to cefiderocol-resistant isolates to identify acquired β-lactamases and mutations in iron-transport-associated genes, including pirA-like or piuA-related changes. These findings are associative: detection of a mutation does not by itself establish that the mutation caused the observed MIC phenotype.

Protocol Parameters

• Collection frame: Include hospitalized inpatient isolates collected across multiple centers; the reference cohort covered 49 sites in six European countries from 1 January through 31 December 2020.
• Organism structure: Analyze P. aeruginosa and Acinetobacter spp. separately because their resistance determinants and therapeutic options differ.
• Resistance stratification: Define meropenem-resistant P. aeruginosa using an MIC greater than 8 mg/L when reproducing the study’s high-dose meropenem comparison.
• Assay interpretation: Report cefiderocol and comparator susceptibility side by side, retaining the species, specimen source, and resistance phenotype for each isolate rather than presenting only an aggregate percentage.
• Molecular follow-up: Use targeted PCR for selected β-lactamase analysis and whole-genome sequencing for cefiderocol-resistant isolates when the objective is to investigate candidate resistance mechanisms.
• Workflow recommendation: Treat these parameters as a surveillance framework, not as a substitute for the laboratory’s validated susceptibility method, current breakpoints, or clinical microbiology quality-control procedures.

Core Findings and Why They Matter

Among all P. aeruginosa isolates, cefiderocol susceptibility was 98.9%, compared with 83.3% to 91.4% for the tested β-lactam/β-lactamase inhibitor combinations. The difference became more pronounced in the 139 meropenem-resistant isolates: cefiderocol susceptibility was 97.8%, whereas comparator susceptibility ranged from 12.2% to 59.7%. These results indicate that cefiderocol retained in vitro activity across a population in which several alternative β-lactam regimens had substantially reduced coverage, according to the study results.

The same pattern appeared among P. aeruginosa resistant to other advanced combinations. Cefiderocol susceptibility was 93.6% to 98.1% in isolates resistant to the tested β-lactam/β-lactamase inhibitor combinations. In isolates resistant to both meropenem and ceftazidime-avibactam, cefiderocol susceptibility was 96.7%, compared with 5.0% to 45.0% for the comparator range. In the meropenem- and ceftolozane-tazobactam-resistant group, cefiderocol susceptibility was 98.4%, while comparator susceptibility ranged from 8.1% to 54.8%. These comparisons support the paper’s conclusion that broad cross-resistance was not apparent in P. aeruginosa.

Activity against Acinetobacter spp. was also substantial, although the pattern differed. Overall cefiderocol and sulbactam-durlobactam susceptibility were 92.4% and 97.0%, respectively. Among 227 meropenem-resistant Acinetobacter isolates, the corresponding values were 85.0% and 93.8%. However, cefiderocol susceptibility fell to 65.8% among cefiderocol-resistant isolates defined within the molecularly investigated group, while sulbactam-durlobactam susceptibility was only 13.3% among its resistant subgroup. The investigators therefore identified sulbactam-durlobactam as a notable exception to the general lack of apparent cross-resistance.

The resistance-gene findings provide biological context. In meropenem-resistant P. aeruginosa, metallo-β-lactamases were prominent, with 30 of 139 isolates carrying such genes and bla_VIM-2 detected in 15 of 139. In meropenem-resistant Acinetobacter spp., oxacillinase genes were dominant: 215 of 227 isolates carried an oxacillinase, including 194 with bla_OXA-23. Among cefiderocol-resistant isolates, acquired β-lactamase genes were found in 1 of 10 P. aeruginosa isolates and 32 of 38 Acinetobacter isolates. Mutations involving pirA-like or piuA loci were identified in 10 of 10 and 37 of 38 isolates, respectively, as reported by the genomic analysis.

These observations are important but should not be overinterpreted. The study measures susceptibility, not direct bactericidal activity against Pseudomonas aeruginosa. It also does not establish that every detected β-lactamase or iron-transport mutation independently determines resistance. Instead, it identifies patterns that can guide confirmatory genetic, biochemical, and longitudinal studies.

Comparison with Existing Internal Articles

The reference study complements the internal article Ceftolozane Sulfate: Assay-to-PK/PD Translation, which focuses on how MIC measurements can be connected to translational experiments. The cefiderocol paper supplies a population-level example of careful susceptibility stratification, while the internal resource addresses the next interpretive step: relating assay results to exposure and infection-model outcomes. These are complementary perspectives, not interchangeable evidence.

It also differs from Modeling P. aeruginosa Resistance to Ceftolozane via ampC/ampD Mutations. That article examines mutation-specific resistance to ceftolozane-tazobactam using semi-mechanistic modeling, whereas the reference study compares cefiderocol with several agents across a geographically distributed isolate collection. Together, they illustrate why resistance research benefits from combining surveillance, molecular characterization, and PK/PD modeling rather than relying on a single evidence layer.

Limitations and Transferability

The geographic scope is a strength, but it also limits direct transferability. The isolates came from six European countries and were collected during one calendar year; local species distributions, antimicrobial exposure, infection-control practices, and resistance genes may differ elsewhere. The collection was also composed of hospitalized inpatient isolates, with respiratory specimens especially common, so the results should not be assumed to represent community infections or every anatomical site.

Another limitation is that the study is an in vitro susceptibility investigation. It did not include a neutropenic mouse thigh infection model, clinical treatment outcomes, or pharmacokinetic/pharmacodynamic (PK/PD) studies. Consequently, high susceptibility percentages do not by themselves establish optimal dosing, tissue exposure, bactericidal effect, or clinical success. The findings are most transferable to laboratory surveillance and comparative assay design, while treatment decisions still require patient-specific assessment and validated clinical guidance.

Finally, the molecular analysis was concentrated on selected resistant phenotypes and was not designed to prove causality for each genetic alteration. Future work should test whether the reported changes reproducibly shift cefiderocol MIC values across genetic backgrounds and whether resistance emerges or reverts under defined antimicrobial exposure. The paper’s strongest practical message is therefore methodological: test promising options in parallel, then investigate discordant results rather than inferring susceptibility from resistance to another β-lactam alone.

Research Support Resources

Researchers designing related susceptibility, resistance-surveillance, or translational assay workflows can use Ceftolozane sulfate (SKU C8753) as a research reagent for Ceftolozane-focused studies. It should be treated as a complementary tool rather than a substitute for cefiderocol testing, and experiments should follow validated assay procedures and supplier handling guidance.